Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Mar 14, 2024 8:45pm
87 Views
Post# 35934019

RE:RE:RE: PLWH and Nash

RE:RE:RE: PLWH and Nash

I think it's up to the Doctors', discretion as in case of PLWH the disease can progress faster than the general population so with currently only one drug approved they might bite the bullet and go with it however since HiV patients were excluded one can question MDGL's drug efficacy on this subgroup as HIV liver is prone to fat accumulation and fat in some cases can act as a toxic substance cussing inflammations/infections. Also if the drug's label specifically excludes PLWH it might be an insurance issue. 



 

palinc2000 wrote:

If HIV patients are diagnosed for Nash they would not be prescribed the Madrigal drug?

scarlet1967 wrote:

Exclusion criteria

Patients who meet any of the following criteria will be excluded from participation in the study...."

Known immunocompromised status, including but not limited to individuals who have undergone organ transplantation, who are known to be positive for HIV or who have recurrent or chronic systemic bacterial, fungal, viral or protozoal infections."

https://www.nature.com/articles/s41591-023-02603-1

I don't believe they had any HIV positive patients enrolled in their trial like most of the current trials.

 




palinc2000 wrote: We were told a few years ago that FDA insisted that THTX proposed Phase 3 trial include the general Nash population and not only PLWH .....In hindsight that was bad news since THTX could not handle such a large trial

Does anyone have access if any to the subset data from the Madrigal trial on results in theur Phase 3 trial for PLWH?
Scarlett and or Qwerty are the only posters imo on this MB who could find out  but of course others are invited also
Maybe just maybe there could be an opportunity for going back to the original Nash protocol to include only PLWH



 


 


 

<< Previous
Bullboard Posts
Next >>